Send to

Choose Destination
Oncotarget. 2017 Jul 4;9(2):2728-2738. doi: 10.18632/oncotarget.18964. eCollection 2018 Jan 5.

Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis.

Zhao ZX1,2, Lu LW1,2, Qiu J1,2, Li QP1,2, Xu F1,2, Liu BJ1,2, Dong JC1,2, Gong WY1,2.

Author information

Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
The Academy of Integrative Medicine of Fudan University, Shanghai 200032, P.R. China.



Glucose transporter-1 (GLUT-1) as the major glucose transporter present in human cells is found overexpressed in a proportion of human malignancies. This meta-analysis is attempted to assess the prognostic significance of GLUT-1 for survival in various cancers.

Materials and Methods:

We conducted an electronic search using the databases PubMed, Embase and Web of Science, from inception to Oct 20th, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.


Fourty-one studies with a total of 4794 patients were included. High GLUT-1 expression was significantly associated with poorer prognosis [overall survival: HR = 1.833 (95% CI: 1.597-2.069, P < 0.0001); disease-free survival: HR = 1.838 (95% CI: 1.264-2.673, P < 0.0001); progression-free survival: HR = 2.451 (95% CI: 1.668-3.233, P < 0.0001); disease specific survival: HR = 1.96 (95% CI: 1.05-2.871, P < 0.0001)].


High GLUT-1 expression may be an independent prognostic marker to predict poor survival in various types of cancers. Further clinical trials with high quality need to be conducted to confirm our conclusion.


GLUT-1; Glucose transporter-1; cancer; meta-analysis; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no competing interests in relation to the work described.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center